{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:59:54Z","timestamp":1784627994246,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006197","name":"The A.P. M\u00f8ller Foundation for the Advancement of Medical Science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006308","name":"Helga and Peter Korning\u2019s Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006308","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Frimodt-Heineke Foundation"},{"name":"Oda and Hans Svenningsen\u2019s Foundation"},{"name":"Direkt\u00f8r Emil C. Hertz and spouse Inger Hertz\u2019 Foundation"},{"name":"Frode Nygaard and Spouse\u2019s Foundation"},{"name":"Dagmar Marshall\u2019s Foundation"},{"DOI":"10.13039\/501100007436","name":"Torben and Alice Frimodt\u2019s Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Aase and Ejnar Danielsen\u2019s Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glucocorticoids (GCs), such as prednisolone, are widely used to treat inflammatory diseases. Continuously long-term or high dose treatment with GCs is one of the most common causes of secondary osteoporosis and is associated with sarcopenia and increased risk of debilitating osteoporotic fragility fractures. Abaloparatide (ABL) is a potent parathyroid hormone-related peptide analog, which can increase bone mineral density (aBMD), improve trabecular microarchitecture, and increase bone strength. The present study aimed to investigate whether GC excess blunts the osteoanabolic effect of ABL. Sixty 12\u201313-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC\u2009+\u2009ABL. ABL was administered as subcutaneous injections (100\u00a0\u03bcg\/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10\u00a0mg). The study lasted four weeks. GC induced a substantial reduction in muscle mass, trabecular mineral apposition rate (MAR) and bone formation rate (BFR\/BS), and endocortical MAR compared with Control, but did not alter the trabecular microarchitecture or bone strength. In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS\/BS), MAR, BFR\/BS, and bone strength compared with Control. However, when administered concomitantly with GC, the osteoanabolic effect of ABL on BMC, cortical morphology, and cortical bone strength was blunted. In conclusion, at cortical bone sites, the osteoanabolic effect of ABL is generally blunted by short-term GC excess.<\/jats:p>","DOI":"10.1038\/s41598-021-91729-8","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T10:04:33Z","timestamp":1623319473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice"],"prefix":"10.1038","volume":"11","author":[{"given":"Mikkel Bo","family":"Brent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Skovhus","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Br\u00fcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"91729_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-319-62470-9_3","volume-title":"Contemporary Endocrinology","author":"BM Arafah","year":"2018","unstructured":"Arafah, B. M. Pharmacology of glucocorticoids. In Contemporary Endocrinology 67\u201381 (Humana Press Inc., 2018). https:\/\/doi.org\/10.1007\/978-3-319-62470-9_3."},{"key":"91729_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4187\/respcare.06314","volume":"63","author":"DM Williams","year":"2018","unstructured":"Williams, D. M. Clinical pharmacology of corticosteroids. Respir. Care 63, 655\u2013670 (2018).","journal-title":"Respir. Care"},{"key":"91729_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes, J. N. et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 66, 1560\u20131567 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"91729_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/09546639909056008","volume":"10","author":"MW Greaves","year":"1999","unstructured":"Greaves, M. W. & Gatti, S. The use of glucocorticoids in dermatology. J. Dermatol. Treat. 10, 83\u201391 (1999).","journal-title":"J. Dermatol. Treat."},{"key":"91729_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/rheumatology\/keaa035","volume":"59","author":"I Neumann","year":"2020","unstructured":"Neumann, I. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis. Rheumatology (Oxford) 59, 60\u201367 (2020).","journal-title":"Rheumatology (Oxford)"},{"key":"91729_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1681\/ASN.2011111112","volume":"23","author":"J Lv","year":"2012","unstructured":"Lv, J. et al. Corticosteroid therapy in IgA nephropathy. J. Am. Soc. Nephrol. 23, 1108\u20131116 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"91729_CR7","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.72147","volume-title":"Corticosteroids","author":"IA Janahi","year":"2018","unstructured":"Janahi, I. A., Rehman, A. & Baloch, N. A. Corticosteroids and their use in respiratory disorders. In Corticosteroids (InTech, 2018). https:\/\/doi.org\/10.5772\/intechopen.72147."},{"key":"91729_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","volume":"872","author":"MA Pufall","year":"2015","unstructured":"Pufall, M. A. Glucocorticoids and cancer. Adv. Exp. Med. Biol. 872, 315\u2013333 (2015).","journal-title":"Adv. Exp. Med. Biol."},{"key":"91729_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/DHPS.S7197","volume":"2","author":"J Payer","year":"2010","unstructured":"Payer, J., Brazdilova, K. & Jackuliak, P. Management of glucocorticoid-induced osteoporosis: Prevalence, and emerging treatment options. Drug Healthc. Patient Saf. 2, 49\u201359 (2010).","journal-title":"Drug Healthc. Patient Saf."},{"key":"91729_CR10","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley, L. & Humphrey, M. B. Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 379, 2547\u20132556 (2018).","journal-title":"N. Engl. J. Med."},{"key":"91729_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr.21796","volume":"65","author":"RA Overman","year":"2013","unstructured":"Overman, R. A., Yeh, J. Y. & Deal, C. L. Prevalence of oral glucocorticoid usage in the United States: A general population perspective. Arthritis Care Res. 65, 294\u2013298 (2013).","journal-title":"Arthritis Care Res."},{"key":"91729_CR12","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/art.21194","volume":"52","author":"JR Curtis","year":"2005","unstructured":"Curtis, J. R. et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 52, 2485\u20132494 (2005).","journal-title":"Arthritis Rheum."},{"key":"91729_CR13","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","volume":"16","author":"AC Feldstein","year":"2005","unstructured":"Feldstein, A. C., Elmer, P. J., Nichols, G. A. & Herson, M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos. Int. 16, 2168\u20132174 (2005).","journal-title":"Osteoporos. Int."},{"key":"91729_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 339, 292\u2013299 (1998).","journal-title":"N. Engl. J. Med."},{"key":"91729_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3899\/jrheum.081207","volume":"36","author":"SA Stoch","year":"2009","unstructured":"Stoch, S. A. et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial. J. Rheumatol. 36, 1705\u20131714 (2009).","journal-title":"J. Rheumatol."},{"key":"91729_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253\u20131263 (2009).","journal-title":"Lancet"},{"key":"91729_CR17","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028\u20132039 (2007).","journal-title":"N. Engl. J. Med."},{"key":"91729_CR18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag, K. G. et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: Final results of a twenty-four\u2013month randomized, double-blind double-dummy trial. Arthritis Rheumatol. 71, 1174\u20131184 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"91729_CR19","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer, R. M. et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434\u20131441 (2001).","journal-title":"N. Engl. J. Med."},{"key":"91729_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.bone.2006.01.142","volume":"39","author":"H Oxlund","year":"2006","unstructured":"Oxlund, H. et al. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39, 244\u2013252 (2006).","journal-title":"Bone"},{"key":"91729_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00223-010-9370-3","volume":"87","author":"AR Doyon","year":"2010","unstructured":"Doyon, A. R., Ferries, I. K. & Li, J. Glucocorticoid attenuates the anabolic effects of parathyroid hormone on fracture repair. Calcif. Tissue Int. 87, 68\u201376 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"91729_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller, P. D. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial. JAMA - J. Am. Med. Assoc. 316, 722\u2013733 (2016).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"91729_CR23","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41594-018-0151-4","volume":"25","author":"J Ehrenmann","year":"2018","unstructured":"Ehrenmann, J. et al. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nat. Struct. Mol. Biol. 25, 1086\u20131092 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"91729_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrendo.2015.139","volume":"11","author":"RW Cheloha","year":"2015","unstructured":"Cheloha, R. W., Gellman, S. H., Vilardaga, J. P. & Gardella, T. J. PTH receptor-1 signalling\u2014Mechanistic insights and therapeutic prospects. Nat. Rev. Endocrinol. 11, 712\u2013724 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"91729_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-010-0465-9","volume":"68","author":"JP Vilardaga","year":"2011","unstructured":"Vilardaga, J. P., Romero, G., Friedman, P. A. & Gardella, T. J. Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm. Cell. Mol. Life Sci. 68, 1\u201313 (2011).","journal-title":"Cell. Mol. Life Sci."},{"key":"91729_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","volume":"29","author":"N Doyle","year":"2018","unstructured":"Doyle, N. et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos. Int. 29, 685\u2013697 (2018).","journal-title":"Osteoporos. Int."},{"key":"91729_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fendo.2021.628994","volume":"12","author":"MB Brent","year":"2021","unstructured":"Brent, M. B., Stoltenborg, F. E., Br\u00fcel, A. & Thomsen, J. S. Teriparatide and abaloparatide have a similar effect on bone in mice. Front. Endocrinol. 12, 328 (2021).","journal-title":"Front. Endocrinol."},{"key":"91729_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.bone.2018.02.026","volume":"110","author":"A Lodberg","year":"2018","unstructured":"Lodberg, A. et al. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia. Bone 110, 326\u2013334 (2018).","journal-title":"Bone"},{"key":"91729_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.bone.2018.02.017","volume":"110","author":"MB Brent","year":"2018","unstructured":"Brent, M. B., Br\u00fcel, A. & Thomsen, J. S. PTH (1\u201334) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats. Bone 110, 244\u2013253 (2018).","journal-title":"Bone"},{"key":"91729_CR30","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N du Percie Sert","year":"2020","unstructured":"du Percie Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, e3000410 (2020).","journal-title":"PLoS Biol."},{"key":"91729_CR31","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.mex.2020.101079","volume":"7","author":"MB Brent","year":"2020","unstructured":"Brent, M. B., Lodberg, A., Thomsen, J. S. & Br\u00fcel, A. Rodent model of disuse-induced bone loss by hind limb injection with botulinum toxin A. MethodsX 7, 101079 (2020).","journal-title":"MethodsX"},{"key":"91729_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bonr.2017.12.001","volume":"8","author":"MB Brent","year":"2018","unstructured":"Brent, M. B., Thomsen, J. S. & Br\u00fcel, A. The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice. Bone Rep. 8, 9\u201317 (2018).","journal-title":"Bone Rep."},{"key":"91729_CR33","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468\u20131486 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"91729_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28, 2\u201317 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"91729_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3389\/fendo.2019.00923","volume":"10","author":"N Bravenboer","year":"2020","unstructured":"Bravenboer, N. et al. Standardised nomenclature, abbreviations, and units for the study of bone marrow adiposity: Report of the Nomenclature Working Group of the International Bone Marrow Adiposity Society. Front. Endocrinol. 10, 923 (2020).","journal-title":"Front. Endocrinol."},{"key":"91729_CR36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jbmr.3930","volume":"35","author":"C Le Henaff","year":"2020","unstructured":"Le Henaff, C. et al. Abaloparatide at the same dose has the same effects on bone as PTH (1\u201334) in mice. J. Bone Miner. Res. 35, 714\u2013724 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"91729_CR37","doi-asserted-by":"publisher","first-page":"115651","DOI":"10.1016\/j.bone.2020.115651","volume":"142","author":"A Makino","year":"2020","unstructured":"Makino, A. et al. Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: A comparison with teriparatide. Bone 142, 115651 (2020).","journal-title":"Bone"},{"key":"91729_CR38","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1210\/endo.142.11.8515","volume":"142","author":"GK Chan","year":"2001","unstructured":"Chan, G. K., Deckelbaum, R. A., Bolivar, I., Goltzman, D. & Karaplis, A. C. PTHrP inhibits adipocyte differentiation by down-regulating PPAR\u03b3 activity via a MAPK-dependent pathway. Endocrinology 142, 4900\u20134909 (2001).","journal-title":"Endocrinology"},{"key":"91729_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.cellsig.2015.12.012","volume":"28","author":"S Larsson","year":"2016","unstructured":"Larsson, S., Jones, H. A., G\u00f6ransson, O., Degerman, E. & Holm, C. Parathyroid hormone induces adipocyte lipolysis via PKA-mediated phosphorylation of hormone-sensitive lipase. Cell. Signal. 28, 204\u2013213 (2016).","journal-title":"Cell. Signal."},{"key":"91729_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ebiom.2019.01.026","volume":"40","author":"A Fajol","year":"2019","unstructured":"Fajol, A. & Komaba, H. Additional evidence for the role of parathyroid hormone in adipose tissue browning. EBioMedicine 40, 3\u20134 (2019).","journal-title":"EBioMedicine"},{"key":"91729_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bone.2019.03.038","volume":"123","author":"S Costa","year":"2019","unstructured":"Costa, S., Fairfield, H. & Reagan, M. R. Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents. Bone 123, 211\u2013223 (2019).","journal-title":"Bone"},{"key":"91729_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphys.2015.00012","volume":"6","author":"TP Braun","year":"2015","unstructured":"Braun, T. P. & Marks, D. L. The regulation of muscle mass by endogenous glucocorticoids. Front. Physiol. 6, 12 (2015).","journal-title":"Front. Physiol."},{"key":"91729_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.afos.2015.07.008","volume":"1","author":"GL Klein","year":"2015","unstructured":"Klein, G. L. The effect of glucocorticoids on bone and muscle. Osteoporos. Sarcopenia 1, 39\u201345 (2015).","journal-title":"Osteoporos. Sarcopenia"},{"key":"91729_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00198-015-3308-6","volume":"27","author":"W Yao","year":"2016","unstructured":"Yao, W. et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos. Int. 27, 283\u2013294 (2016).","journal-title":"Osteoporos. Int."},{"key":"91729_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2015.01.001","volume":"74","author":"W Dai","year":"2015","unstructured":"Dai, W. et al. Prevention of glucocorticoid induced bone changes with beta-ecdysone. Bone 74, 48\u201357 (2015).","journal-title":"Bone"},{"key":"91729_CR46","doi-asserted-by":"publisher","first-page":"e0154677","DOI":"10.1371\/journal.pone.0154677","volume":"11","author":"X Li","year":"2016","unstructured":"Li, X., Zhou, Z. Y., Zhang, Y. Y. & Yang, H. L. IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse. PLoS ONE 11, e0154677 (2016).","journal-title":"PLoS ONE"},{"key":"91729_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2010.08.011","volume":"49","author":"LI Plotkin","year":"2011","unstructured":"Plotkin, L. I., Bivi, N. & Bellido, T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 49, 122\u2013127 (2011).","journal-title":"Bone"},{"key":"91729_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbspin.2012.01.009","volume":"80","author":"B Bouvard","year":"2013","unstructured":"Bouvard, B., Gallois, Y., Legrand, E., Audran, M. & Chappard, D. Glucocorticoids reduce alveolar and trabecular bone in mice. Jt. Bone Spine 80, 77\u201381 (2013).","journal-title":"Jt. Bone Spine"},{"key":"91729_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"Weinstein, R. S., Jilka, R. L., Michael Parfitt, A. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts end osteocytes by glucocorticoids potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274\u2013282 (1998).","journal-title":"J. Clin. Invest."},{"key":"91729_CR50","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1359\/JBMR.051103","volume":"21","author":"NE Lane","year":"2006","unstructured":"Lane, N. E. et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21, 466\u2013476 (2006).","journal-title":"J. Bone Miner. Res."},{"key":"91729_CR51","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1096\/fj.11-182519","volume":"25","author":"J Jia","year":"2011","unstructured":"Jia, J. et al. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 25, 3366\u20133376 (2011).","journal-title":"FASEB J."},{"key":"91729_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.steroids.2008.11.009","volume":"74","author":"M Herrmann","year":"2009","unstructured":"Herrmann, M. et al. The challenge of continuous exogenous glucocorticoid administration in mice. Steroids 74, 245\u2013249 (2009).","journal-title":"Steroids"},{"key":"91729_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep36513","volume":"6","author":"A Ersek","year":"2016","unstructured":"Ersek, A. et al. Strain dependent differences in glucocorticoid-induced bone loss between C57BL\/6J and CD-1 mice. Sci. Rep. 6, 1\u201310 (2016).","journal-title":"Sci. Rep."},{"key":"91729_CR54","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.2337\/db14-1192","volume":"64","author":"Y Tamura","year":"2015","unstructured":"Tamura, Y. et al. Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice. Diabetes 64, 2194\u20132206 (2015).","journal-title":"Diabetes"},{"key":"91729_CR55","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"Sato, A. Y. et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost\/sclerostin. J. Bone Miner. Res. 31, 1791\u20131802 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"91729_CR56","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.bbrc.2014.03.149","volume":"447","author":"T Fumoto","year":"2014","unstructured":"Fumoto, T. et al. Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia. Biochem. Biophys. Res. Commun. 447, 407\u2013412 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"91729_CR57","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1210\/en.2011-0170","volume":"152","author":"RS Weinstein","year":"2011","unstructured":"Weinstein, R. S. et al. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152, 3323\u20133331 (2011).","journal-title":"Endocrinology"},{"key":"91729_CR58","doi-asserted-by":"publisher","first-page":"E587","DOI":"10.1152\/ajpendo.00219.2016","volume":"311","author":"M Piemontese","year":"2016","unstructured":"Piemontese, M., Xiong, J., Fujiwara, Y., Thostenson, J. D. & O\u2019Brien, C. A. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am. J. Physiol. Endocrinol. Metab. 311, E587\u2013E593 (2016).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"91729_CR59","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/art.24445","volume":"60","author":"LC Hofbauer","year":"2009","unstructured":"Hofbauer, L. C. et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 60, 1427\u20131437 (2009).","journal-title":"Arthritis Rheum."},{"key":"91729_CR60","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/jbmr.1688","volume":"27","author":"S Thiele","year":"2012","unstructured":"Thiele, S. et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J. Bone Miner. Res. 27, 2242\u20132250 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"91729_CR61","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bone.2011.06.013","volume":"49","author":"H Henneicke","year":"2011","unstructured":"Henneicke, H. et al. Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone 49, 733\u2013742 (2011).","journal-title":"Bone"},{"key":"91729_CR62","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00223-009-9301-3","volume":"85","author":"A Postnov","year":"2009","unstructured":"Postnov, A., De Schutter, T., Sijbers, J., Karperien, M. & De Clerck, N. Glucocorticoid-induced osteoporosis in growing mice is not prevented by simultaneous intermittent PTH treatment. Calcif. Tissue Int. 85, 530\u2013537 (2009).","journal-title":"Calcif. Tissue Int."},{"key":"91729_CR63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/JOE-14-0508","volume":"224","author":"L Grahnemo","year":"2015","unstructured":"Grahnemo, L. et al. Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density. J. Endocrinol. 224, 97\u2013108 (2015).","journal-title":"J. Endocrinol."},{"key":"91729_CR64","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3389\/fendo.2020.588773","volume":"11","author":"MB Brent","year":"2020","unstructured":"Brent, M. B., Thomsen, J. S. & Br\u00fcel, A. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar. Front. Endocrinol. 11, 808 (2020).","journal-title":"Front. Endocrinol."},{"key":"91729_CR65","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00223-018-0422-4","volume":"103","author":"A Makino","year":"2018","unstructured":"Makino, A. et al. Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: A comparison with teriparatide. Calcif. Tissue Int. 103, 289\u2013297 (2018).","journal-title":"Calcif. Tissue Int."},{"key":"91729_CR66","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00198-019-04999-4","volume":"30","author":"H Chandler","year":"2019","unstructured":"Chandler, H., Brooks, D. J., Hattersley, G., Bouxsein, M. L. & Lanske, B. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporos. Int. 30, 1607\u20131616 (2019).","journal-title":"Osteoporos. Int."},{"key":"91729_CR67","doi-asserted-by":"publisher","first-page":"100291","DOI":"10.1016\/j.bonr.2020.100291","volume":"13","author":"H Arlt","year":"2020","unstructured":"Arlt, H. et al. Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice. Bone Rep. 13, 100291 (2020).","journal-title":"Bone Rep."},{"key":"91729_CR68","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1002\/art.23954","volume":"58","author":"W Yao","year":"2008","unstructured":"Yao, W. et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 58, 3485\u20133497 (2008).","journal-title":"Arthritis Rheum."},{"key":"91729_CR69","first-page":"2","volume":"9","author":"SH Tella","year":"2017","unstructured":"Tella, S. H., Kommalapati, A. & Correa, R. Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis. Cureus 9, 2 (2017).","journal-title":"Cureus"},{"key":"91729_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley, G., Dean, T., Corbin, B. A., Bahar, H. & Gardella, T. J. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157, 141\u2013149 (2016).","journal-title":"Endocrinology"},{"key":"91729_CR71","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley, M. Abaloparatide: First global approval. Drugs 77, 1363\u20131368 (2017).","journal-title":"Drugs"},{"key":"91729_CR72","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fendo.2020.00065","volume":"11","author":"J Tratwal","year":"2020","unstructured":"Tratwal, J. et al. Reporting guidelines, review of methodological standards, and challenges toward harmonization in bone marrow adiposity research. Report of the methodologies working group of the international bone marrow adiposity society. Front. Endocrinol. 11, 65 (2020).","journal-title":"Front. Endocrinol."},{"key":"91729_CR73","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3109\/17453674.2010.483986","volume":"81","author":"L Baofeng","year":"2010","unstructured":"Baofeng, L. et al. Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop. 81, 396\u2013401 (2010).","journal-title":"Acta Orthop."},{"key":"91729_CR74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00774-007-0797-1","volume":"26","author":"S Casta\u00f1eda","year":"2008","unstructured":"Casta\u00f1eda, S. et al. Characterization of a new experimental model of osteoporosis in rabbits. J. Bone Miner. Metab. 26, 53\u201359 (2008).","journal-title":"J. Bone Miner. Metab."},{"key":"91729_CR75","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1210\/endo.142.3.8048","volume":"142","author":"AW Eberhardt","year":"2001","unstructured":"Eberhardt, A. W., Yeager-Jones, A. & Blair, H. C. Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid-treated rabbits. Endocrinology 142, 1333\u20131340 (2001).","journal-title":"Endocrinology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91729-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:32:11Z","timestamp":1670059931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91729-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91729"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91729-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12258"}}